Novel, highly potent, selective 5-HT2A/D2 receptor antagonists as potential atypical antipsychotics

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 4, 2003, Pages 767-770

  Lee, Taekyu ^a   Robichaud, Albert J ^a   Boyle, Kristopher E ^a   Lu, Yimin ^a   Robertson, David W ^a   Miller, Keith J ^a   Fitzgerald, Larry W ^a   McElroy, John F ^a   Largent, Brian L ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BUTYROPHENONE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

ARTICLE; CHIRAL CHROMATOGRAPHY; CYCLIZATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FRIEDEL CRAFTS REACTION; HUMAN; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

EID: 0037294430     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)01028-4     Document Type: Article

References (31)

1. Reynolds G.P. Trends Pharmacol. Sci. 13:1992;116.
2. Andreason, N. C., Ed. In Schizophrenia. From Mind to Molecule, American Psychiatric: Washington, DC, 1994.
3. Ross B.S., Ramsey L.A. Drug Topics. 145:2001;75.
4. Creese I., Burt D.R., Synder S.H. Science. 192:1976;481.
5. Martin, A. R. In Burger's Medicinal Chemistry and Drug Discovery, 5th ed.; Wolf, M. E., Ed.; Wiley-Interscience: New York, 1997, Vol. 5, p 195.
6. Rowley M., Bristow L.J., Hutson P.H. J. Med. Chem. 44:2001;477.
7. (a) Lowe J.A. III, Seeger T.F., Vinick F. J. Med. Res. Rev. 8:1988;475
8. (b) Filton A., Heel R.C. Drugs. 40:1990;722
9. (c) Meltzer H.Y. J. Clin. Psychiatry. 55:1994;45
10. (a) Lowe J.A. III, Seeger T.F., Vinick F. J. Med. Res. Rev. 8:1988;475 (b) Filton A., Heel R.C. Drugs. 40:1990;722 (c) Meltzer H.Y. J. Clin. Psychiatry. 55:1994;45 (d) Rosenheck R., Cramer J., Xu W., Henderson W., Frismann L. N. Engl. J. Med. 337:1997;385.
11. Sanders-Bush, E.; Mayer, S. E. In The Pharmacological Basis of Therapeutics, 9th ed., Hardman, J. G., Limbird, L. E., Molinoff, P. B., Ruddon, R. W., Goodman, A., Eds.; McGraw-Hill: New York, 1996; p 249.
12. Leysen J.E., Janssen P.M., Megens A.A., Schotte A. J. Clin. Psychiatry. 55:1994;5.
13. Kehne J.H. J. Pharm. Exp. Ther. 277:1996;968.
14. Sorbera L.A., Silvestre J., Castaner J. Drugs Future. 23:1998;955.
15. Scrip; July 1999, 2458, 21.
16. Nyberg S., Nakashima Y., Nordstrom A.-L., Halldin C., Farde L. Br. J. Psychiatry. 168:1996;40.
17. Meltzer H.Y., Matsubara S., Lee C.-C. Psycopharmacol. Bull. 25:1989;390.
18. Raviña E., Masaguer C.F. Curr. Med. Chem.: Cent. Nerv. Syst. Agents. 1:2001;43.
19. Lieberman J.A., Hohn C.A., Mikane J., Rai K., Pisciotta A.V., Salz B.L., Howard A. J. Clin. Psychiatry. 49:1988;271.
20. (a) Cunnigham Owens D.G. Drugs. 51:1996;895
21. (b) Wirshing D.A., Wirshing W.C., Kysar L., Berisford M.A., Goldsteing D., Pahsdag J., Mintz J., Marder S.R. J. Clin. Psychiatry. 60:1999;358
22. (c) Green B. Curr. Med. Res. Opin. 15:1999;79.
23. Robichaud, A. J.; Lee, T.; Deng, W.; Mitchell, I. S.; Haydar, S.; Chen, W.; McClung, C. D.; Calvello, E. J. B.; Zawrotny, D. M. PCT Int. Appl., 2000, WO 0077010.
24. Schwarcz, R.; Varasi, M.; Della Torre, A.; Speciale, C., Bianchetti; A. PCT Int. Appl., 1995, WO 9504714.
25. (a) Brewster J.H. Top. Stereochem. 2:1967;1
26. (b) Brewster J.H. J. Am. Chem. Soc. 81:1959;5493
27. (c) Brewster J.H. J. Am. Chem. Soc. 81:1959;483
28. (d) Brewster J.H. J. Am. Chem. Soc. 81:1959;5475.
29. (a) Fitzgerald L.W., Conklin D.S., Krause C.M., Marshall A.P., Patterson J.P., Tran D.P., Iyer G., Kostich W.A., Largent B.L., Hartig P.R. J. Neurochem. 72:1999;2127
30. (b) Nelson D.L., Lucaites V.L., Wainscott D.B., Glennon R.A. Naunyn-Schmiedeberg's Arch. Pharmacol. 359:1999;1.
31. Malick J.B., Doren E., Barnett A. Pharmacol. Biochem. Behav. 6:1977;325.